Drug Evaluation: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Lansoprazole: A new proton pump inhibitor for the treatment of peptic ulceration and reflux oesophagitis

References

• BLACK, TW, DUNCAN WAM, DURA,NT Gj, GANELLIN CR,PARSONS ME: Definition and antagonism of histamine H2 receptors. Nature (1972) 236:385–390.
   PubMed Web of Science ®Google Scholar
• LANZON-MILLER S, POUNDER RE, HAMILTON MR, BALL S,CHROMOS NAF, RAYMOND F, ALAUSSON M, CEDERBERG C: Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Alimentary Pbarmacol. Ther. (1987) 1:239–251.
   PubMedGoogle Scholar
• GRAHAM DY: A reliable cure for Helicobacter infection? Gut 09951 37:154–156.
   Google Scholar
• WORMSLEY KG: Achlorhydria, hypergastrinaemia, car- cinoids: a flawed hypothesis. Gut (1986) 28:488–505.
   Google Scholar
• LARSSON H, CARLSSON E, HAKANSON R, MATTSSON H, •NILSSON G, SEENSALU R, WALLMARK B, SUNDLER F:Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid se-cretion: studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology (1988) 95:1477–1486. •
   Google Scholar
• SJOSTRAND SE, RYBERG B, OLBE L: Stimulation andinhibition of add secretion in the isolated guinea-pig gastric mucosa. Ada Physiologica Scandinavica (1978) Special Suppl. Gastric Ion Transport:181–185.
   Google Scholar
• LONGDON W, BARTH H, DAMMANN HG: Dose-related healing of duodenal ulcer with the proton pump inhibi- tor lansoprazole. Alimentary Pharmacol. Ther. (1991) 5:245–254.
   PubMed Web of Science ®Google Scholar
• FELLENIUS E, BERGLINDH T, SACHS G, OLBE L, ELANDER •B, SJOSTRAND SE, WALLMARK B: Substituted benzimida- zoles block acid secretion by blocking the 11 . 1K + ATPas e. Nature (1981) 290:159–161.
   Google Scholar
• SACHS G, SHIN JM, BESANCON M, PRINZ C: The continu- ing development of gastric proton pump inhibitors. Alimentary Pharmacol. Ther. (1993) 7\(Suppl. 1):4–12.
   Google Scholar
• SACHS G, KAUNITZ J, MENDELEIN J, WALLMARK B: Bio- chemistry of gastric add secretion: HVIC-ATPase. In: Handbook of Physiology - The Gastrointestinal System (Sec-tion 6, Volume III, Chapter 12). American Physiological Society, Bethesda (1989):229–253.
   Google Scholar
• FORTE JG, OKAMOTO CT, CHOW DC, CANFIELD VA, LEVENSON R: Specialization of the apical surface of parietal cells: identification and characterization of a 13-subunit of the gastric ir /le ATPase. In: Mechanisms of Injury, Protection and Repair of the Upper Gastrointestinal Tract. Garner A, O'Brien PE (Eds.), Wiley, Chichester (1991):187–198.
   Google Scholar
• SATOH H, INATOMI N, NAGAYA H, INADA I, NORHARAA, NAKAMURA N, MAKI Y: Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J. Pharmacol. Exp. Ther. (1989) 248:806–815.
   PubMed Web of Science ®Google Scholar
• GARNER A, CHANDRANATH I, HASAN MY, BASTAKI SMA,AL-TAJIR GK, SCHMASSMANN A: Relative merits of two novel antisecretory drugs acting via If/le-ATPase in- hibition and CCK receptors. Gut (1993) 34:S54.
   PubMedGoogle Scholar
• INATOMI N, NAGAYA H, TAKAMI K, SHINO A, SATOH H:Effects of a proton pump inhibitor, AG-1749 (lansopra-zole), on reflux esophagitis and experimental ulcers in rats. Jpn. J. Pharmacol. (1991) 55:437–451.
   PubMedGoogle Scholar
• BERGMANN JF, CHASSANY 0, SIMONEAU G: Protectionagainst aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologi- cal responses. Clin. Pharmacol. Ther. (1992) 52:413–416.
   PubMed Web of Science ®Google Scholar
• MULLER P. DA1MMANN HG, LEUCHT U, SIMON B: Human gastric acid secretion following repeated doses of AG- 1749. Alimentary Pharmacol. Ther. (1989) 3:193–198.
   PubMed Web of Science ®Google Scholar
• BERLIN I, MOLINIER P, DUCHIER A: Dose ranging studyof lansoprazole, a new proton pump inhibitor, in patients with high gastric add secretion. Eur. J. Clin. Pharmacol. (1992)43:117–119.
   PubMed Web of Science ®Google Scholar
• BELL NCV, CHIBA N, RINGHAM GL, HUNT RH: Time tomaximum effect of lansoprazole on gastric pH in male normal volunteers. Gastroenterology (1992) 101:A345.
   Google Scholar
• MOULES IK, GARRETT A, BROCKLEBANK D: Gastric acidinhibition by proton pump Inhibitor lansoprazole is unaffected by food. Br. J. Clin. Pract. (1993) 4:153–161.
   Google Scholar
• MOULES 1K: Lansoprazole: pharmacokinetics and phar-macodynamics. Br. J. Chn. Pract. (1994) 40\(Suppl. 75):41–i5.
   Google Scholar
• ABE T, SATO S, SUZUKI T, MIYAJIMA H: Thirteen week oral toxicity study of lansoprazole (AG-1749) in rats. Jpn Pharmacol. Ther. (1990) 18:9–24.
   Google Scholar
• ATKINSON JE, DALY IW, BOLTE HF, MORISHIMA H, SASAKI S: One-year oral gavage toxicity study of lanso- prazole (AG-1749) in rats. Jpn. J. Pharmacol. Tiler. (1990) 18:59-91. GARNER A Gastric tumours induced by antisecretory agents: hypergastrinaemia, structure-activity and other considerations. Reseach and Clinical Forums (1990) 1245–57.
   Google Scholar
• EKMAN L, HANSSON E, HAVU N, CARLSSON E, LUNDBERG C: Toxicological studies on omeprazole. Scand. J. Gas-troenterol. (1985) 20\(Suppl. 108):53–69.
   Google Scholar
• CARUANA P, AZZONI C, BERTELE A, ANNIBALE B, FRANZEA, DELLEFAVE G, BORDI C: Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment. Histopathology (1992) 21:359–363.
   PubMed Web of Science ®Google Scholar
• BERGMANN JF, FORESTIER S, JOUBERT M: Evolution ofgastrinaemia after treatment with lansoprazole in duo- denal ulcer (DU) and reflux esophagitis (RE). Gastroen-terology (1993) 104:A42.
   Web of Science ®Google Scholar
• MAKIYAMA K, UMENE Y, MURATA I, IZUNO M, HARA K: Clinical study on therapeutic effect of an antiulcer agent, lansoprazole, on gastric ulcer with special refer- ence to serum gastrin concentration. Yakuri to Cbiryo (1991) 19:307–325.
   Google Scholar
• EISSELE R, BRUNNER G, FISCHER B: Evaluation of entero-chromaffInlike (ECL) cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology (1993) 104:A74.
   Web of Science ®Google Scholar
• DELHOTAL-LANDES B, FLOUVAT B, DUCHIER J, MOLINIEP, DELLATOLAS F, LEMAIRE M: Pharmacokinetics of Ian-soprazole in patients with renal or liver disease of varying severity. Eur. J. Clin. Pharmacol. (1993) 45:367–371.
   PubMed Web of Science ®Google Scholar
• TATENO M, NAKAMURA N: Phase I study of lansoprazole (AG-1749) antiulcer agent: capsule form. Rinsho Iyaku (1991) 7:51–62.
   Google Scholar
• FLOUVAT B, DELHOTAL-LANDES B, COURNOT A: Singleand multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br.J. Chn. Pharmacol. (1993) 36:467–469.
   PubMed Web of Science ®Google Scholar
• HUSSEIN Z, GRANNEMAN GR, MUKHERJEE D, SAMARA E,HOGAN DL, KOSS MA, ISENBERG JI: Age-related differ-ences in the pharmacokinetics and pharmocody- namics of lansoprazole. Br. J. Clin. Pharrnacol. (1993) 36:467–469.
   PubMedGoogle Scholar
• COSTE T, LOGEAIS C, DELHOTAL-LANDES B: Pharmacok-inetics of lansoprazole after repeated administration in cirrhosis patients. Gastroenterology (1993) 104:A59.
   Web of Science ®Google Scholar
• CURI-PEDROSA R, PICIIARD L, BONFILS C: Major implica-tions of cytochrome P4503A4 in the oxidative metabo-lism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepato- cytes. Br. J. Clin. Pract. (1993) 36:156.
   Google Scholar
• BARDHAN KD, HAWKEY cj, LONG RG, MORGAN AG,WORMSLEY KG, MOUES I, BROCKLEBANK D: Lanso- prazole versus ranitidine for the treatment of reflux esophagitis. Alimentary Pharmacol. Ther. (1995) 9:145–151.23. • • •
   Google Scholar
• ROBINSON M, SAHBA B, AVNER D, JHALAS N, GRESKI-ROSE PA, JENNINGS DE: A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Alimentary Pharmacol. Ther. (1995) 9:25–31.
   PubMed Web of Science ®Google Scholar
• HATLEBAKK JG, BERSTAD A, CARLING L, SVEDBERG LE, UNGE P: Lansoprazole versus omeprazole in short-term treatment of reflux esophagitis: results of a Scandina-vian muhicentre trial Scand. J. Gastmenterol. (1993) 28:224–228.
   Web of Science ®Google Scholar
• GOUGH AL: lansoprazole is superior to ranitidine 300mg bd in prevention of relapse of reflux oesophagitis. Gut (1994) 35:558.
   Google Scholar
• BARDHAN KD, AHLBERG J, HISLOP WS, LINDHOLMER C,LONG RG, MORGAN AG, SJOSTEDT S, SMITH PM, STIG R, WORMSLEY KG, LANGWORTHY H, MOULES IK: Rapid healing of gastric ulcers with lansoprazole. Alimentary Pharmacol. Ther. (1994) 8:215–220.
   PubMed Web of Science ®Google Scholar
• MICHEL P, LEMAIRE M, COLIN R, BOMMELAER G, RAM- BAUD JC, DUTAS JL, BIGARD MA, VERWAERD JC: Treat-ment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical triaL Alimentary Pharmacol. Ther. (1994) 8:119–122.
   Google Scholar
• FLORENT C, FOREST1ER S, JOUBERT-COULLIN M: Lanso-prazole versus omeprazole: efficacy and safety in acute gastric ulcer. First European Gastroenterology Week, 25–30 September, 1992. Athens, Greece.
   Google Scholar
• HAWKEY CJ, BARDHAN KD, LONG RG, WORMSLEY KG, COCHRAN RM, CHRISTIAN J, MOULES I: Improved symp-tom relief and duodenal ulcer healing with lansopra-zole compared to ranitidine. Gastroenterology (1991) 100:A80.
   Google Scholar
• FIOTZ J, KLEINERT R, GRYMBOWSKI T, HENNIG U, SCHWARZ J: Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. Alimentary Pharmacol. Ther. (1992) 6:87–96.
   PubMed Web of Science ®Google Scholar
• LANZA F, GOFF J, SILVERS D: lansoprazole for one year prevents recurrence of duodenal ulcer. Gastroenterology (1994) 106,A122.
   Web of Science ®Google Scholar
• PETITE JP, SLAMA JL, LICHT H: Lansoprazole and ome- ?prazole in the treatment of duodenal ulcer: a multicen-tre double-blind comparative triaL Gastroenterologie Clinique Biologie (1993) 17:334–340.
   Google Scholar
• LOUW JA, VAN RENSBERG C, SIMJEE AE: Lansoprazole versus omeprazole in duodenal ulcer healing. South African Med.J. (1993) 83:777.
   Google Scholar
• IWAHI T, SATOH H, NAKAO M, IWASAIU T, YAMAZAKI T, KUBO K: Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selec-tive activity against Helicobacter pylori. Antimicrob. Agents Chem other. (1991) 35:490–496.
   PubMed Web of Science ®Google Scholar
• HARRIS AW, GUMMETI PA, LOGAN RPH, ASHWORTH HM, •BARON JH, MISIEWICZ JJ: Eradication of Helicobacterpylori with lansoprazole and clarithromycin. Alimen-tary Pharmacol. Ther. (1995) 9:201–204.
   PubMed Web of Science ®Google Scholar
• FELMAN M, HARFORD WV, FISHER RS: Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new IrVIC-ATPase inhibitor, a controlled double blind study. Am.J. Gastroenterol. (1993) 88:1212–1217.
   PubMed Web of Science ®Google Scholar
• BRUNNER G, ARNOLD R, HENNIG U: An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranl-tidine treatment Alimentary Pharmacol. Ther. (1993) 7\(Suppl. 1):51–55.
   Google Scholar
• BARDHAN KD: The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Alimentary Pharmacol. Ther. (1995) 9\(Suppl. 1):15–25.
   Google Scholar
• METZ DC, PISEGNA JR, RINGHAM GL, FEIGENBAUM, K, KOV1ACK PD, MATON PN, GARDNER JD, JENSEN RT: Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig. Dis. Sci. (1993) 38:245–256.
   PubMed Web of Science ®Google Scholar
• COLIN-JONES DG: Safety of lansoprazole. Alimentary Pharmacol. Ther. (1993) 7\(Suppl. 1):56–60.
   Google Scholar
• GARNER A: Adaptation in the pharmaceutical industry with particular reference to gastrointestinal drugs and diseases. Scand. J. Gastroenterol. (1992) 27:S83–S89.
   Google Scholar
• CLASSEN M, DELLE FAVE G (Eds.): Management of acid-related diseases: focus on pantoprazole. Alimentary Pharmacol. Ther. (1994) 8\(Suppl. 1).
   Google Scholar
• FUJISAKA H, SHIBATA H, OKETANI K, MURAKAMI M, FUJIMOTO M, WAKABAYASHI T, YAMATSU I, TAGEGUCHI N: Effects of the proton pump inhibitor E3810 on gastric secretion and gastric and duodenal ulcers or erosions in rats. Drug Invest. (1991) 3:328-332. Professor A Garner, Ph.D., D.Sc., Associate Dean for Research, Faculty of Medicine & Health Sciences, United Arab Emirates Uni-versity, PO Box 17666, Al Ain, UAE (Tel: 971 363 0161; Fax: 971 363 0171).
   Google Scholar